9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma

Condition Pleural Mesothelioma|Malignant Pleural Mesothelioma Estimated Enrollment: 70 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 99-124 Study First Received: September 12, 2005 Last Updated: March 26, 2014 Estimated Primary Completion Date: April 2002 Primary Outcome Measures: To determine the maximally tolerated dose of intracavitary cisplatin in patients with malignant pleural mesothelioma,|To quantitate the safety of intraoperative intrathoracic/intraperitoneal hyperthermic cisplatin|to study the pharmacokinetics of cisplatin administered in this way. Sponsors and Collaborators: Dana-Farber Cancer Institute|Brigham and Women's Hospital Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00165555...

Continue reading

A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 17 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: I207 Study First Received: December 1, 2011 Last Updated: September 16, 2016 Estimated Primary Completion Date: April 2014 Primary Outcome Measures: Response Rate|Amount and severity of adverse events|Duration of Response|Blood and tissue marker evaluation Sponsors and Collaborators: NCIC Clinical Trials Group|Canadian Cancer Trials Group Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01486368...

Continue reading

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 89 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: MORAb-009-003 Amatuximab Study First Received: August 19, 2008 Last Updated: November 13, 2015 Estimated Primary Completion Date: June 2011 Primary Outcome Measures: Progression free survival using the EORTC modified RECIST criteria.|Overall response, duration of survival, overall survival and safety. Sponsors and Collaborators: Morphotek Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00738582...

Continue reading

Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma

Condition Malignant Mesothelioma|Perioperative/Postoperative Complications Estimated Enrollment: 44 Age Group: Child, Adult, Senior Gender: All Study Type: Interventional Study Design Allocation: Primary Purpose: Treatment Study ID Numbers: CDR0000068155|CRC-BOC-L52|EU-20033 Study First Received: September 11, 2000 Last Updated: December 18, 2013 Estimated Primary Completion Date: null Primary Outcome Measures: Incidence of metastatic skin nodules Sponsors and Collaborators: University of Glasgow|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00006231...

Continue reading

Bortezomib in Treating Patients With Malignant Pleural Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 33 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 05-10 ICORG|ICORG-05-10|EUDRACT-2005-004420-39|EU-20748 Study First Received: August 8, 2007 Last Updated: December 30, 2014 Estimated Primary Completion Date: December 2009 Primary Outcome Measures: Objective tumor response rate (complete response or partial response) as assessed by modified RECIST criteria|Time to disease progression|Overall survival|Safety|Quality of life Sponsors and Collaborators: Cancer Trials Ireland Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00513877...

Continue reading

Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 32 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: NL25655.031.08 Study First Received: September 27, 2010 Last Updated: February 27, 2017 Estimated Primary Completion Date: November 13, 2012 Primary Outcome Measures: To test the impact of the addition of axitinib to standaard chemotherapy treatment on histology samples|the side effects of the standard chemotherapy and the additional risks related to axitinib use Sponsors and Collaborators: The Netherlands Cancer Institute|Pfizer Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01211275...

Continue reading

Capecitabine in Treating Patients With Malignant Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 27 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CALGB-39807|U10CA031946|CLB-39807|CDR0000067422 Study First Received: January 21, 2000 Last Updated: July 12, 2016 Estimated Primary Completion Date: December 2003 Primary Outcome Measures: Sponsors and Collaborators: Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00004183...

Continue reading

Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 59 Age Group: up to 69 Years   (Child, Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Primary Purpose: Treatment Study ID Numbers: EORTC-08031|2004-004273-28 Study First Received: September 26, 2005 Last Updated: July 17, 2012 Estimated Primary Completion Date: August 2007 Primary Outcome Measures: Feasibility in terms of 90-day progression-free survival|Toxicity|Progression-free survival|Overall survival Sponsors and Collaborators: European Organisation for Research and Treatment of Cancer - EORTC Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00227630...

Continue reading

S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery

Condition Malignant Mesothelioma Estimated Enrollment: 61 Age Group: 18 Years to 120 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000616162|S0722|U10CA032102 Study First Received: October 8, 2008 Last Updated: January 10, 2017 Estimated Primary Completion Date: April 2014 Primary Outcome Measures: Progression-Free Survival|Response|Overall Survival|Frequency and Severity of Toxicities Sponsors and Collaborators: Southwest Oncology Group|National Cancer Institute (NCI) Result Received: October 26, 2016 Website Link: https://ClinicalTrials.gov/show/NCT00770120...

Continue reading

Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite

Condition Malignant Mesothelioma|Pulmonary Complications Estimated Enrollment: 494 Age Group: 25 Years to 80 Years   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case Control|Time Perspective: Prospective Study ID Numbers: CDR0000518348|P30CA022453|WSU-2006-057|WSU-HIC-094806MP2F Study First Received: May 9, 2009 Last Updated: March 4, 2014 Estimated Primary Completion Date: March 2013 Primary Outcome Measures: Identification of potential drug targets for therapeutic strategies to treat asbestos fiber-related diseases Sponsors and Collaborators: Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00897247...

Continue reading